Trial Profile
Open Label, Randomized, Repeated-dose, 3-way Crossover Study to Investigate Pharmacokinetic Interaction and the Safety of Inhaled CHF5259 and CHF6001 Administered in Healthy Subjects Via NEXThaler® Dry Powder Inhaler
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Jan 2017
Price :
$35
*
At a glance
- Drugs Glycopyrrolate (Primary) ; Tanimilast (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors Chiesi Farmaceutici
- 02 Jan 2017 New trial record